A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Public ClinicalTrials.gov record NCT00389090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter, phase II trial, assessing the antitumor activity, and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma.
Study identification
- NCT ID
- NCT00389090
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2006 (Type not available)
- Primary completion
- Jun 2008 (Actual)
- Completion
- Feb 2009 (Actual)
- Last update posted
- Feb 9, 2012
2006 – 2009
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AOI Pharmaceuticals Investigative Site | Los Angeles | California | 90033 | — |
| AOI Pharmaceuticals Investigative Site | Orlando | Florida | 32804 | — |
| AOI Pharmaceuticals Investigative Site | Chicago | Illinois | 60611 | — |
| AOI Pharmaceuticals Investigative Site | Evanston | Illinois | 60201 | — |
| AOI Pharmaceuticals Investigative Site | Lexington | Kentucky | 40536 | — |
| AOI Pharmaceuticals Investigative Site | Louisville | Kentucky | 40202 | — |
| AOI Pharmaceuticals Investigative Site | Minneapolis | Minnesota | 54407 | — |
| AOI Pharmaceuticals Investigative Site | Durham | North Carolina | 27710 | — |
| AOI Pharmaceuticals Investigative Site | Greenville | South Carolina | 29605 | — |
| AOI Pharmaceuticals Investigative Site | Dallas | Texas | 75246 | — |
| AOI Pharmaceuticals Investigative Site | Houston | Texas | 77024 | — |
| AOI Pharmaceuticals Investigative Site | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00389090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2012 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00389090 live on ClinicalTrials.gov.